<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01627795</url>
  </required_header>
  <id_info>
    <org_study_id>OS-MES-P2-01</org_study_id>
    <nct_id>NCT01627795</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment</brief_title>
  <official_title>A Single-center, Open Label Study for Evaluation of the Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment - A Phase IIa Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oshadi Drug Administration</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Oshadi Drug Administration</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Malignant mesothelioma is a rare neoplasm that arises most commonly from the mesothelial&#xD;
      surfaces of the pleural cavity, occasionally from the peritoneal surface, and rarely from the&#xD;
      tunica vaginalis or pericardium. It has an extremely poor prognosis with a median survival of&#xD;
      4 to 13 months for untreated patients 1 and 6 to 18 months for treated patients, regardless&#xD;
      of the therapeutic approach.&#xD;
&#xD;
      The anticancer activity of Oshadi D and Oshadi R treatment was tested in preclinical studies&#xD;
      and in phase I clinical study. Four metastatic mesothelioma patients are treated for 5 to 12&#xD;
      months. The Oshadi D and Oshadi R combination treatment was generally well-tolerated with no&#xD;
      dose-limiting toxicities observed.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Suspended</overall_status>
  <start_date>December 2016</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">August 2018</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse events and serious adverse events occurence</measure>
    <time_frame>One month following treatment initiation</time_frame>
    <description>Adverse events and serious adverse events report</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall survival time</measure>
    <time_frame>12 months</time_frame>
    <description>Overall survival time from treatment initiation</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">17</enrollment>
  <condition>Mesothelioma</condition>
  <arm_group>
    <arm_group_label>Oshadi D and Oshadi R</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>anti cancer agents</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oshadi D and Oshadi R</intervention_name>
    <description>anti cancer agents</description>
    <arm_group_label>Oshadi D and Oshadi R</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically or cytologically proven diagnosis of malignant mesothelioma&#xD;
&#xD;
          -  Man or woman 21 years and above&#xD;
&#xD;
          -  Adequate performance status (ECOG 0, 1, or 2)&#xD;
&#xD;
          -  Patient must have adequate organ function as the following:&#xD;
&#xD;
               -  Absolute neutrophils counts (ANS) &gt; 2500/μL.&#xD;
&#xD;
               -  Platelets &gt; 150,000/μL.&#xD;
&#xD;
               -  Hemoglobin &gt; 10 g/dL.&#xD;
&#xD;
               -  Total Bilirubin &lt; 1.5 Upper Normal Limit (UNL).&#xD;
&#xD;
               -  Alanine aminotransferase (ALT), AST (aspartate aminotransferase)and alkaline&#xD;
                  phosphatase must be &lt; 1.5 times of the upper limit of normal.&#xD;
&#xD;
               -  LDH (lactate dehydrogenase) &lt; 500 int. unit/L&#xD;
&#xD;
               -  Estimated GFR (glomerular filtration rate) &gt; 45 ml/min.&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
          -  Females of childbearing potential and males must be willing to use an effective method&#xD;
             of contraception (hormonal or barrier method of birth control; abstinence) from the&#xD;
             time consent is signed until 6 weeks after treatment discontinuation.&#xD;
&#xD;
          -  Females of childbearing potential must have a negative pregnancy test within 7 days&#xD;
             prior to being registered for protocol therapy.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of liver metastasis&#xD;
&#xD;
          -  Any bone involvement&#xD;
&#xD;
          -  Prior radiotherapy, cytotoxic or biologic systemic treatment&#xD;
&#xD;
          -  Any history of Asthma or COPD (chronic obstructive pulmonary disease) that needs&#xD;
             systemic therapy with steroids for more than 2 weeks during the last 2 years.&#xD;
&#xD;
          -  Treatment with systemic steroids for more then 1 month during the last year.&#xD;
&#xD;
          -  Active smokers that are unable to quite smoking&#xD;
&#xD;
          -  Any treatment with investigational agent within 30 days prior to registration for&#xD;
             protocol therapy.&#xD;
&#xD;
          -  Cerebrovascular accident, transient ischemic attack or myocardial infarction within 6&#xD;
             months prior to registration for protocol therapy.&#xD;
&#xD;
          -  Evidence of pulmonary embolism within 6 months prior to registration for protocol&#xD;
             therapy.&#xD;
&#xD;
          -  Any history of solid or hematologic malignancies.&#xD;
&#xD;
          -  Patient with positive HIV serology at screening.&#xD;
&#xD;
          -  Female patient who are breastfeeding or have a positive pregnancy test at screening or&#xD;
             at any time during the study.&#xD;
&#xD;
          -  Uncontrolled hypertension (&gt; 150/100 mm Hg despite optimal medical therapy).&#xD;
&#xD;
          -  Evidence of ongoing cardiac dysrhythmias of NCI CTCAE (Common Toxicity Criteria for&#xD;
             Adverse Effects) Version 3.0 grade 2.&#xD;
&#xD;
          -  Patients in whom radiation or surgery is indicated&#xD;
&#xD;
          -  Significant swallowing disorders.&#xD;
&#xD;
          -  Small bowel surgery.&#xD;
&#xD;
          -  Suspicion of absorption disruption as a result of abdominal radiation&#xD;
&#xD;
          -  Pre-existing malabsorption syndrome, irritable bowel syndrome or other clinical&#xD;
             situation which could affect oral absorption.&#xD;
&#xD;
          -  Evidence of concurrent (&lt; 5 years) second malignancy&#xD;
&#xD;
          -  Mental disorders.&#xD;
&#xD;
          -  Inability to give written informed consent.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hovav Nehushtan, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <zip>91240</zip>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>June 20, 2012</study_first_submitted>
  <study_first_submitted_qc>June 25, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 26, 2012</study_first_posted>
  <last_update_submitted>April 16, 2018</last_update_submitted>
  <last_update_submitted_qc>April 16, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Malignant Mesothelioma</keyword>
  <keyword>Cancer</keyword>
  <keyword>Anti cancer agents</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Mesothelioma, Malignant</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

